Exact Sciences has launched two major new cancer tests in early 2025—with a third expected later this year—marking what the company calls a “transformative” phase. Its newly FDA-approved Cologuard Plus improves upon the original at-home colorectal screening by reducing false positives through new genetic biomarkers. Meanwhile, Oncodetect, a blood-based circulating tumor DNA (ctDNA) test, aims to track minimal residual disease and recurrence across solid tumors. A third test, Cancerguard EX, a multi-cancer early detection test, is set to launch by year’s end.
These innovations prompted Exact Sciences to raise its annual revenue outlook to $3.07–$3.12 billion, projecting 12% year-over-year growth. The company’s screening business is expected to grow 14%, fueled by momentum in Cologuard and its next-gen successors.